Literature DB >> 8158027

Desferrioxamine-promoted virulence of Yersinia enterocolitica in mice depends on both desferrioxamine type and mouse strain.

I B Autenrieth1, R Reissbrodt, E Saken, R Berner, U Vogel, W Rabsch, J Heesemann.   

Abstract

The effects of desferrioxamine B (DFOB) and G (DFOG) on growth promotion and virulence of Yersinia enterocolitica as well as on T cell activation and proliferation were investigated. Both desferrioxamines promoted growth of Y. enterocolitica O:8 (WA-314) and O:3 (Y-108). DFOB had a greater immunosuppressive effect on T cells than did DFOG. These results suggest a dual role of DFOB in yersiniosis: growth promotion of the pathogen and immunosuppression of the host. The LD50 of both Yersinia strains for mice was reduced by DFOB but not by DFOG. However, the LD50 of yersiniae was reduced by DFOB to a greater extent in Yersinia-resistant C57BL/6 than in Yersinia-susceptible BALB/c mice. The different impact of DFOB on the LD50 of Y. enterocolitica in C57BL/6 and BALB/c mice might be due to an immunomodulating effect of DFOB.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158027     DOI: 10.1093/infdis/169.3.562

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Application of comparative phylogenomics to study the evolution of Yersinia enterocolitica and to identify genetic differences relating to pathogenicity.

Authors:  Sarah L Howard; Michael W Gaunt; Jason Hinds; Adam A Witney; Richard Stabler; Brendan W Wren
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

2.  Chitin microparticles for the control of intestinal inflammation.

Authors:  Katsuya Nagatani; Sen Wang; Victoria Llado; Cindy W Lau; Zongxi Li; Atsushi Mizoguchi; Cathryn R Nagler; Yoshimi Shibata; Hans-Christian Reinecker; J Rodrigo Mora; Emiko Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2012-01-12       Impact factor: 5.325

3.  Conjugation of hydroxyethyl starch to desferrioxamine (DFO) modulates the dual role of DFO in Yersinia enterocolitica infection.

Authors:  S Schubert; I B Autenrieth
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

4.  Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica.

Authors:  Biliana Lesic; Jeannine Foulon; Elisabeth Carniel
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Transfer of the core region genes of the Yersinia enterocolitica WA-C serotype O:8 high-pathogenicity island to Y. enterocolitica MRS40, a strain with low levels of pathogenicity, confers a yersiniabactin biosynthesis phenotype and enhanced mouse virulence.

Authors:  Cosima Pelludat; Michael Hogardt; Jürgen Heesemann
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

6.  Contribution of the major secreted yops of Yersinia enterocolitica O:8 to pathogenicity in the mouse infection model.

Authors:  Konrad Trülzsch; Thorsten Sporleder; Emeka I Igwe; Holger Rüssmann; Jürgen Heesemann
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.

Authors:  Jong W Yu; Sabyasachi Bhattacharya; Niranjan Yanamandra; David Kilian; Hong Shi; Sapna Yadavilli; Yuliya Katlinskaya; Heather Kaczynski; Michael Conner; William Benson; Ashleigh Hahn; Laura Seestaller-Wehr; Meixia Bi; Nicholas J Vitali; Lyuben Tsvetkov; Wendy Halsey; Ashley Hughes; Christopher Traini; Hui Zhou; Junping Jing; Tae Lee; David J Figueroa; Sara Brett; Christopher B Hopson; James F Smothers; Axel Hoos; Roopa Srinivasan
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.